Altimmune Announces Publication In The Lancet Of 24-Week Efficacy And Safety Data From Ongoing IMPACT Phase 2b Trial Of Pemvidutide In Patients With MASH
Benzinga Newsdesk 12 months ago
News
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profileSignificant improvements observed in secondary endpoints,
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile
Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis
GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The Lancet of 24-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a paper titled "Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study".